Nuvectis Pharma Inc (NVCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $696.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
Nuvectis Pharma Inc (NVCT) Stock Forecast
Analysts expect Nuvectis Pharma (NVCT) to earn -$2.03 per share in the fiscal year ending Dec 31, 2026. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 33.3% |
| Buy | 4 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$2.03
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.70
- EPS consensus
- Next report
- Feb 9, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.03 | -$2.54 to -$1.87 | 6 |
| Dec 31, 2027 | -$1.70 | -$2.32 to -$1.06 | 6 |
Quarterly Estimates
The EPS consensus rises from -$0.38 for the quarter ending Dec 31, 2026 to -$0.28 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.38 | -$0.79 to -$0.21 | 8 |
| Mar 31, 2027 | -$0.28 | -$0.34 to -$0.22 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.03 | -$1.04 | -$1.04 | -$1.04 | -$1.00 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.70 | -$1.15 | -$1.15 | -$1.15 | -$1.13 | N/A |
| Quarter ending Mar 31, 2027 | -$0.28 | -$0.33 | -$0.33 | -$0.33 | N/A | N/A |
Frequently Asked Questions About NVCT
What is the NVCT stock forecast?
Consensus analyst estimates put Nuvectis Pharma's EPS at -$2.03 for the fiscal year ending Dec 31, 2026. The consensus rating from 6 analysts is Buy.
How do analysts rate NVCT stock?
Of 6 analysts covering Nuvectis Pharma, 2 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NVCT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.03, with estimates from -$2.54 to -$1.87 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.70, with estimates from -$2.32 to -$1.06 from 6 analysts.
How many analysts cover NVCT?
6 analysts rate Nuvectis Pharma stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NVCT pages: Overview, Earnings, Forecast, Financials, Competitors